Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005792 · ClinicalTrials.gov registry record · Phase 1
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
A Phase 1 study of Multiple Myeloma and Plasma Cell Neoplasm, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 131
- Enrollment target
- 1
- Study location
NCT00005792: Completed Phase 1 study of Multiple Myeloma and Plasma Cell Neoplasm, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
NCT00005792 is a Phase 1 study of Multiple Myeloma and Plasma Cell Neoplasm that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 131 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005792, a Phase 1 study of Multiple Myeloma and Plasma Cell Neoplasm, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 131 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combination chemotherapy plus peripheral stem cell transplantation in treating patients who have multiple myeloma.
Primary Outcome
To determine the incidence and duration of CTCAE v3, grade 3 or 4 mucositis for modified dose level four.
Conditions Studied
Interventions
- DRUG melphalan
- DRUG topotecan
- DRUG etoposide phosphate
- PROCEDURE Autologous Stem Cell Rescue
Study Locations (1)
Florida
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 1998-06-02 |
| Est. Completion | 2018-11-01 |
| Phase | Phase 1 |
What the finished NCT00005792 record still lists
NCT00005792 is an interventional study that assigns participants to a tested intervention. The registered 131 participants enrollment target is mid-sized for trials with a published cap, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (76% lower).
The record links to 2 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which melphalan is the first listed.
NCT00005792 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT00005792 about?
NCT00005792 is a clinical study titled "Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase I/II tri...
What is the current status of trial NCT00005792?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 131 participants. The study started on 1998-06-02. Estimated completion is 2018-11-01.
What conditions does trial NCT00005792 study?
This clinical trial studies the following conditions: Multiple Myeloma, Plasma Cell Neoplasm.
What interventions are being tested in trial NCT00005792?
The interventions under investigation include: melphalan (DRUG), topotecan (DRUG), etoposide phosphate (DRUG), Autologous Stem Cell Rescue (PROCEDURE).
Who is sponsoring clinical trial NCT00005792?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00005792 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00005792's enrollment target sits among peer trials
131 144th of 438 higher than 295 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03051464 · 131 participants · Phase 2
No Surgery Trial / Two Dose-escalation Strategies
- NCT04301843 · 131 participants · Phase 2
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
- NCT04748549 · 131 participants · NA
Intraoperative VR for Older Patients Undergoing TKA
- NCT05951179 · 131 participants · Phase 2
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI